Stephen Brady
Chairman
Tempest Therapeutics, Inc. (TPST)Equibles does not estimate personal net worth.
Get an email with a short summary when Tempest Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get TPST alertsAbout Stephen Brady
Stephen Brady is recorded as Chairman at Tempest Therapeutics, Inc. (TPST) since November 19, 2025. Tempest Therapeutics, Inc. reported in an 8-K filed May 22, 2026 that Stephen Brady resigned as Board of Directors, effective May 22, 2026. Tempest Therapeutics, Inc. reported in an 8-K filed February 6, 2026 that Stephen Brady resigned as President and Chief Executive Officer of the Company, effective February 3, 2026. Tempest Therapeutics, Inc. reported in an 8-K filed February 6, 2026 that Stephen Brady was appointed Chair of the Board, effective February 3, 2026. Equibles holds 4 filed executive changes naming Stephen Brady; each is listed under recent activity with its source filing. The proxy statement of Tempest Therapeutics, Inc. reports total compensation of $2,299,475 for Stephen Brady in fiscal 2025, including a base salary of $906,400. Disclosed compensation is on record for 5 fiscal years. Tempest Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Tempest Therapeutics, Inc. includes Louis J. Arcudi III (CEO and Board Member), Matt Angel (CEO and Board Member), Matt Angel, Ph.D. (CEO and Board Member) and 7 others.
“On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.”
“On February 3, 2026, immediately following the Closing, Mr. Brady resigned from his positions of President and Chief Executive Officer of the Company.”
Affiliation history
-
Current
2025-11-19–present
-
2021-01-01–2026-05-22
-
Start not stated–2026-02-03
Company network
Leadership on record at Tempest Therapeutics, Inc.
- Louis J. Arcudi III CEO, Board Member
- Matt Angel CEO, Board Member
- Matt Angel, Ph.D. CEO, Board Member
- Matthew Angel CEO, Board Member
- Stephen R. Brady CEO
- Julia C. Owens Chairman
- Mike Raab Chairman, Board Member
- Constance Ames CFO
- Jennifer Minai-Azary CFO
- Justin Trojanowski CFO, Chief Accounting Officer
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Tempest Therapeutics, Inc. (TPST) | Former Chief Executive Officer and President | $906,400 | $2,299,475 |
| 2024 | Tempest Therapeutics, Inc. (TPST) | Former Chief Executive Officer and President | $600,000 | $1,872,299 |
| 2023 | Tempest Therapeutics, Inc. (TPST) | Chief Executive Officer and President | $567,000 | $7,007,407 |
| 2022 | Tempest Therapeutics, Inc. (TPST) | Chief Executive Officer and President | $530,000 | $1,514,366 |
| 2021 | Tempest Therapeutics, Inc. (TPST) | Chief Executive Officer | $475,283 | $714,721 |